🧠 Food for thought

Implications, context, and why it matters.

Oncare’s model could tap into gaps in India’s fragmented drug buying market

• Oncare’s claim that it can cut chemotherapy costs by 40% sounds plausible because many hospitals still buy cancer drugs one by one.
• Mid-sized, non-branded hospitals often purchase high-cost oncology medicines on their own, which leaves them with little bargaining power and can push prices up for patients 1.
• A network of oncology departments across these hospitals could combine orders through pooled procurement, which can bring down per-unit prices.
• India’s National Cancer Grid negotiated for 23 centers and reached median savings of 82% versus maximum retail prices for a set of oncology and supportive care drugs 1.
• Lower prices matter because one study cited in a systematic review estimated that a standard early-stage HER2+ (human epidermal growth factor receptor 2-positive) breast cancer regimen could cost about 10 years of average annual wages in India (and South Africa) 2.

Success could spread cancer care beyond India’s largest cities

• Oncare plans to expand into tertiary cities in Uttar Pradesh, Bihar, and West Bengal, which would move care beyond the usual big-city focus 3.
• Specialized oncology services cluster in large urban hospitals, which can force patients from smaller towns to pay for travel and accommodation as well as treatment 2.
• Building and running oncology departments inside existing mid-sized, non-branded hospitals could bring specialist services closer to home 3.
• If the partnership model works, it could offer a template for delivering other complex medical services outside major metropolitan hubs.